Prestige Consumer Healthcare Inc.

Listed Company

PBHCIK 0001295947NYSELarge AcceleratedPharmaceutical PreparationsFY ends Mar 31

Period

FY 2026

Revenue

$1.09B

Net Income

$190.30M

Total Assets

$3.49B

Equity

$1.89B

Shares Out

47.37M

Op. Cash Flow

$257.63M

PBH$49.92−33.56% · past yearDBEQ Basic

Daily closing prices

Business

Prestige Consumer Healthcare Inc. develops, manufactures, markets and distributes over-the-counter health and personal care products under well-recognized brands including BC & Goody's, Chloraseptic, Compound W, Dramamine, Fleet, Gaviscon, Monistat, Nix and Summer's Eve. The company sells through mass merchandisers, drug stores, food, dollar, convenience and club stores and e-commerce channels across North America and international markets including Australia. Operations are organized into North American OTC Healthcare and International OTC Healthcare segments, with the North American segment representing the substantial majority of revenues.

Summary from 10-K filed 2026-05-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Total revenues	1,089	1,138	1,125	1,128	1,087
Cost of sales excluding depreciation	483	494	493	495	459
Cost of sales depreciation	10	9	8	8	7
Cost of sales	493	503	501	502	466
Gross profit	596	634	624	625	621
Advertising and marketing	149	156	153	145	157
General and administrative	116	108	106	107	107
Depreciation and amortization	21	21	23	25	25
Goodwill and tradename impairment	0	12	0	370	1
Total operating expenses	286	298	282	648	291
Operating income	309	337	342	−22	330
Interest expense, net	42	48	67	69	64
Other expense (income), net	10	5	−756,000	2	1
Total other expense, net	52	53	66	72	67
Income before income taxes	257	284	276	−94	262
Provision for income taxes	67	70	67	−12	57
Net income	190	215	209	−82	205
Basic (in USD per share)	3.93	4.32	4.21	−1.65	4.09
Diluted (in USD per share)	3.91	4.29	4.17	−1.65	4.04
Basic (in shares)	48	50	50	50	50
Diluted (in shares)	49	50	50	50	51
Currency translation adjustments	9	−3	−3	−12	−1
Unrecognized net (loss) gain on pension plans	−96,000	−81,000	9,000	334,000	246,000
Total other comprehensive income (loss)	9	−3	−3	−13	769,000
Comprehensive income	200	211	206	−95	206

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Cash and cash equivalents	64	98	46	58	27
Accounts receivable, net of allowance of $18,187 and $16,314, respectively	192	194	177	167	139
Inventories	159	148	139	162	120
Prepaid expenses and other current assets	17	8	13	4	6
Total current assets	431	448	375	392	293
Property, plant and equipment, net	122	75	77	70	71
Operating lease right-of-use assets	28	28	11	15	20
Finance lease right-of-use assets, net	22	25	2	4	7
Goodwill	581	527	528	528	579
Intangible assets, net	2,300	2,295	2,321	2,342	2,697
Other long-term assets	11	3	6	3	3
Total Assets	3,494	3,402	3,318	3,354	3,671
Accounts payable	23	19	39	63	56
Accrued interest payable	16	16	16	16	4
Operating lease liabilities, current portion	7	6	5	7	6
Finance lease liabilities, current portion	3	2	1	3	3
Other accrued liabilities	73	63	56	73	74
Total current liabilities	121	107	117	161	143
Long-term debt, net	994	992	1,126	—	—
Deferred income tax liabilities	447	420	404	380	445
Long-term operating lease liabilities, net of current portion	21	23	8	10	16
Long-term finance lease liabilities, net of current portion	18	21	172,000	2	5
Other long-term liabilities	6	5	9	8	7
Total Liabilities	1,607	1,567	1,663	1,907	2,093
Commitments and Contingencies Note 17	—	—	—	—	—
Preferred stock $0.01 par value, Authorized 5,000 shares, Issued and outstanding None	0	0	0	0	0
Issued 56,010 shares at March 31, 2025 and 55,501 shares at March 31, 2024	562,000	560,000	555,000	548,000	544,000
Additional paid-in capital	609	593	567	535	516
Treasury stock, at cost 8,892 shares at March 31, 2026 and 6,501 shares at March 31, 2025	−439	−277	−220	−189	−134
Accumulated other comprehensive loss, net of tax	−28	−38	−34	−32	−19
Retained earnings	1,746	1,556	1,341	1,132	1,214
Total Stockholders Equity	1,888	1,835	1,655	1,447	1,578
Total Liabilities and Stockholders Equity	3,494	3,402	3,318	3,354	3,671

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31
Depreciation and amortization	31	30	31	33	32
Loss on sale or disposal of property and equipment	165,000	234,000	274,000	273,000	271,000
Deferred and other income taxes	23	14	23	−61	10
Amortization of debt origination costs	2	2	5	4	4
Stock-based compensation costs	11	11	14	12	—
Non-cash operating lease cost	8	7	6	6	7
Write-off of supplier loan	10	0	0	—	—
Impairment loss	0	12	0	370	1
Other	0	1	0	447,000	−9,000
Accounts receivable	−4	−16	−6	−25	−25
Inventories	−2	−9	24	−42	663,000
Prepaid expenses and other current assets	−7	5	−8	2	1
Accounts payable	−151,000	−19	−25	7	9
Accrued liabilities	3	7	−16	11	10
Operating lease liabilities	−8	−8	−7	−7	−6
Other	32,000	−898,000	−1	−275,000	−725,000
Net cash provided by operating activities	258	252	249	230	260
Purchases of property, plant and equipment	−11	−8	−10	−8	−10
Acquisitions, net of cash acquired	−124	−8	−11	0	−247
Other	−2	−978,000	0	−4	177,000
Net cash used in investing activities	−137	−17	−20	−12	−257
Term Loan repayments	0	−135	−225	−135	−600
Borrowings under revolving credit agreement	40	0	0	20	85
Repayments under revolving credit agreement	−40	0	0	−20	−85
Net increase in line of credit	3	0	0	—	—
Payment of debt costs	0	0	−769,000	0	−6
Payments of finance leases	−2	−5	−3	−3	−3
Proceeds from exercise of stock options	4	15	18	7	7
Fair value of shares surrendered as payment of tax withholding	−4	−6	−6	−5	−3
Repurchase of common stock	−156	−52	−25	−50	0
Other	−246,000	0	0	—	—
Net cash used in financing activities	−156	−182	−241	−186	−8
Effects of exchange rate changes on cash and cash equivalents	1	−573,000	180,000	−982,000	−959,000
(Decrease) increase in cash and cash equivalents	−34	51	−12	31	−5
Interest paid	44	48	63	54	61
Income taxes paid	46	52	60	41	47

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Prestige Consumer Healthcare Inc.'s CIK number?

Prestige Consumer Healthcare Inc.'s SEC CIK number is 0001295947 (1295947). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Prestige Consumer Healthcare Inc.'s SEC filings?

All of Prestige Consumer Healthcare Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Prestige Consumer Healthcare Inc. last report earnings?

Prestige Consumer Healthcare Inc. (PBH) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001295947-26-000013). This is Prestige Consumer Healthcare Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Prestige Consumer Healthcare Inc.'s most recent earnings 8-K?

Prestige Consumer Healthcare Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001295947-26-000013. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Prestige Consumer Healthcare Inc.'s latest earnings 8-K →
Look up any company's CIK number →